Australian Clinical Labs Limited provided earnings guidance for the five months ended 31 May 2022. For the period, the company does not expect to be down more than 1% on the previous corresponding period (excluding revenue from COVID and acquisitions) and the company does not expect to depart materially from Bloomberg forecasts for NPAT for the full financial year to 30 June 2022 (excluding acquisition transaction costs).